# ReCode Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/recode-therapeutics

- Industry: Biotechnology
- Headquarters: Menlo Park, US
- Website: http://www.recodetx.com
- Total disclosed funding: $288M
- Latest round: Series B (Sep 28, 2023)
- Investors on record: 19

## About

Based in the US, ReCode Therapeutics, Inc. is a biotechnology company focused on developing innovative genetic therapies for genetically defined diseases with limited treatment options. ReCode Therapeutics, Inc. specializes in advanced genetic medicines targeting diseases like primary ciliary dyskinesia and cystic fibrosis. Founded in 2015 in Menlo Park, California, the company has completed 7 funding deals. The latest funding round, raising USD 29 million from returning investor Cystic Fibrosis Foundation and new investor Praxis Precision Medicines, Inc. on September 29, 2025. The company was co-founded by Daniel Siegwart and Michael Torres. David Lockhart serves as CEO.ReCode Therapeutics develops advanced genetic medicines targeting diseases with limited treatment options, specifically primary ciliary dyskinesia and cystic fibrosis. The company focuses on innovative delivery systems that enhance the effectiveness of genetic therapeutics across multiple administration routes. ReCode's products cater to healthcare providers and research institutions in North America and Europe, aiming to improve the lives of patients with rare genetic disorders. ReCode Therapeutics generates revenue through strategic partnerships and collaborations with biopharmaceutical companies and academic institutions, focusing on joint research and development initiatives. These partnerships often involve shared funding for proprietary therapies, such as RCT2100, which recently received Orphan Drug Designation from the U.S. FDA for cystic fibrosis treatment. Revenue structures include milestone payments and royalties tied to the commercialization of developed therapies, leveraging innovative solutions in genetic medicine. In September 2025, ReCode Therapeutics, Inc. raised USD 29 million in venture debt funding from returning investor Cystic Fibrosis Foundation and other unspecified investors. The company plans to introduce new genetic therapies aimed at addressing additional genetic disorders by 2025, while also targeting expansion into European markets to broaden its reach. Recent funding will be utilized to enhance R&D capabilities, ensuring a robust pipeline of innovative therapies for patients.

## Funding rounds

- Series B, Sep 28, 2023, $100M — OrbiMed Advisors, Amgen Ventures, OUP (Osage University Partners), MPM BioImpact, Pfizer Venture Investments, Sanofi Ventures, EcoR1 Capital, Vida Ventures, Leaps by Bayer, Solasta Ventures, AyurMaya, Bioluminescence Ventures
- Series B, Jun 29, 2022, $120M — Amgen Ventures, Matrix Capital Management, Leaps by Bayer
- Series B, Oct 13, 2021, $40M — OrbiMed Advisors, Colt Ventures, Covera Ventures, OUP (Osage University Partners), Tekla Capital Management, MPM BioImpact, Pfizer Venture Investments, Sanofi Ventures, EcoR1 Capital, Timefolio Capital, Vida Ventures, Superstring Capital Management
- Series A, Mar 6, 2020, $28M — OrbiMed Advisors, Colt Ventures, OUP (Osage University Partners), MPM BioImpact, Hunt Technology Ventures, Vida Ventures

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B
- Colt Ventures (https://capitalatlas.ai/funds/colt-ventures) — Series A, Series B
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A, Series B
- MPM BioImpact (https://capitalatlas.ai/funds/mpm-bioimpact) — Series A, Series B
- Hunt Technology Ventures — Series A
- Vida Ventures (https://capitalatlas.ai/funds/vida-ventures) — Series A, Series B
- Covera Ventures (https://capitalatlas.ai/funds/covera-ventures) — Series B
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series B
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series B
- Sanofi Ventures (https://capitalatlas.ai/funds/sanofi-ventures) — Series B
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series B
- Timefolio Capital — Series B
- Superstring Capital Management (https://capitalatlas.ai/funds/superstring-capital-management) — Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B
- Matrix Capital Management — Series B
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series B
- Solasta Ventures (https://capitalatlas.ai/funds/solasta-ventures) — Series B
- AyurMaya — Series B
- Bioluminescence Ventures (https://capitalatlas.ai/funds/bioluminescence-ventures) — Series B